Summary

Elevance Health's Q4 2025 earnings call (Jan 28, 2026) reveals a fundamental recalibration of Medicare Advantage economics. Management deliberately shrinking membership (high teens % decline in 2026) to preserve margins, exiting unprofitable PPO products, and permanently resetting long-term margin targets to "mid-single-digit" from prior framework.

Critical cross-ticker signal: UnitedHealth (Jan 27) and Elevance (Jan 28) both independently reported MA membership shrinkage, margin-over-volume prioritization, and reimbursement inadequacy within 24 hours. This is an industry-level structural shift, not company-specific noise.

Key Evidence

1. Margin Target Recalibration (LR 3.5)

  • Long-term health benefits margin target lowered to "mid-single-digit"
  • Drivers: (1) elevated cost trends, (2) ACA larger share vs commercial group, (3) business mix
  • Management emphasizes "not a change in strategy or discipline" — this is permanent reset

2. Medicare Advantage Strategic Exit (LR 3.5)

  • High teens % membership decline in 2026 (deliberate)
  • Exiting unprofitable PPO products, focusing D-SNP/HMO
  • Targeting >100 bps margin improvement to at least 2%
  • Management choosing profitability over volume

3. Medicare Reimbursement Pressure (LR 3.0)

  • Advance Notice "effectively flat" — doesn't keep pace with cost trends
  • Management publicly pushing back on reimbursement adequacy
  • Risk adjustment framework changes creating uncertainty
  • Industry-wide pressure confirmed by UNH transcript same week

4. Medicaid Trough Year (LR 2.0)

  • 2026 margin guidance: -1.75% (trough year)
  • Cost trend mid-single-digit % (2x historical, but moderating)
  • Rate increases lag trend despite being mid-single-digit %

5. 2026 Guidance Reset (LR 1.8)

  • EPS guidance: at least $25.50 (vs $30.29 in 2025, -16%)
  • 2025 included $3.75 nonrecurring items (tax benefits)
  • Reaffirms 12% long-term growth algorithm starting 2027
  • Clean baseline being set

Investment Implications

Bear case strengthened:

  • Margin compression is structural, not cyclical — ACA mix shift + cost environment durably lower than prior framework
  • Medicare reimbursement pressure industry-wide — flat Advance Notice creates ongoing tension
  • 2026 is transition/trough year with EPS down ≈16% excluding nonrecurring items

Bull case:

  • Strategic discipline evident — exiting unprofitable MA markets despite volume hit
  • Medicaid stabilizing — 2026 called "trough year" with moderation expected
  • Cash flow improving materially — $5.5B+ OCF in 2026 supports capital return
  • 12% long-term growth algorithm reaffirmed for 2027+

Market disconnect: Stock at $345 (-11.8% over 1Y), analyst consensus $392 (+13.7% upside, 68% buy ratings). Street assumes 2027 growth resumption at prior margins. Evidence suggests permanent margin reset to mid-single-digit.

Key question: Is the margin framework change fully priced? Stock will trade on whether 2027 growth resumption is credible given the reset baseline.

Alpha location: Market may be underpricing structural margin reset across managed care MA segment. Cross-ticker convergence (UNH + ELV within 24hrs) confirms this is industry-wide, not isolated to one operator.